Antidiabetic treatment and COVID-19 Outcomes: A population-based cohort study in primary health care in Catalonia during the first wave of the pandemic
Dan Ouchi, Carles Vilaplana-Carnerero, Vanessa De Dios, Maria Giner-Soriano, Rosa Morros
Primary Care Diabetes, doi:10.1016/j.pcd.2022.10.001
To analyse if antidiabetic treatment was associated with better COVID-19 outcomes in type 2 diabetic patients, measured by hospital admission and mortality rates as severe outcomes. Methods: Cohort study including COVID-19 patients registered in the Primary Care electronic records, in March-June 2020, comparing exposed to metformin in monotherapy with exposed to any other antidiabetic. Data source: SIDIAP (Information System for Research in Primary Care), which captures clinical information of 5,8 million people from Catalonia, Spain. Results: We included 31,006 diabetic patients infected with COVID-19, 43.7% previously exposed to metformin, 45.5% of them in monotherapy. 16.4% were admitted to hospital and 15.1% died. Users of insulin in monotherapy (OR 1.29, 95% CI 1.11-1.50), combined with metformin (OR 1.38, 1.13-1.69) or IDPP4 alone (OR 1.29, 1.03-1.63) had higher risk of severe outcomes than those in metformin monotherapy. Users of any insulin (OR 1.61, 1.32-1.97) or combined with metformin (OR 1.69, 1.30-2.20) had a higher risk of mortality. Conclusions: Patients receiving metformin monotherapy in our study showed a lower risk of hospitalization and death in comparison to those treated with other frequent antidiabetic agents. We cannot distinguish if better outcomes are related with the antidiabetic therapy or with other factors, such as metabolic control or interventions applied during the hospital admission.
Conflict of interest The authors declare no conflict of interest.
References
Almalki, Qayyum, Irfan, Haider, Glowacz et al., A novel method for COVID-19 diagnosis using artificial intelligence in chest X-ray images, Healthc,
doi:10.3390/healthcare9050522Belančić, Kresović, Troskot Dijan, Glucagon-like peptide-1 receptor agonists in the era of COVID -19: Friend or foe?, Clin. Obes,
doi:10.1111/cob.12439Bornstein, Rubino, Khunti, Mingrone, Hopkins et al., Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30152-2Catsalut, Servei Català de la Salut, Conjunt mínim bàsic de dades
Chen, Lv, Lin, Arshad, Dai, The association between antidiabetic agents and clinical outcomes of COVID-19 patients with diabetes: a bayesian network meta-analysis, Front. Endocrinol,
doi:10.3389/FENDO.2022.895458Chen, Yang, Cheng, Chen, Peng et al., Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care,
doi:10.2337/DC20-0660Drucker, Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications, Endocr. Rev,
doi:10.1210/endrev/bnaa011Fadini, Morieri, Longato, Avogaro, Prevalence and impact of diabetes among people infected with SARS-CoV-2, J. Endocrinol. Investig,
doi:10.1007/s40618-020-01236-2Kan, Zhang, Han, Xu, Ye et al., Mortality risk of antidiabetic agents for type 2 diabetes with COVID-19: a systematic review and meta-analysis, Front. Endocrinol,
doi:10.3389/FENDO.2021.708494/BIBTEXKatsiki, Ferrannini, Anti-inflammatory properties of antidiabetic drugs: a "promised land" in the COVID-19 era?, J. Diabetes Its Complicat,
doi:10.1016/j.jdiacomp.2020.107723Kieffer, Mc Intosh, Pederson, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology,
doi:10.1210/ENDO.136.8.7628397Landstra, De Koning, COVID-19 and diabetes: understanding the interrelationship and risks for a severe course, Front. Endocrinol,
doi:10.3389/fendo.2021.649525Li, Zhang, Yang, Lian, Xie et al., The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike, IScience,
doi:10.1016/J.ISCI.2020.101160Lipsitch, Swerdlow, Finelli, Defining the epidemiology of Covid-19 -studies needed, N. Engl. J. Med,
doi:10.1056/NEJMp2002125Luo, Qiu, Liu, Liu, Zheng et al., Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am. J. Trop. Med. Hyg,
doi:10.4269/AJTMH.20-0375Mcgurnaghan, Robertson, Murray Mscph, Mcmenamin Mbchb, Phd et al., Articles Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland, Www. Thelancet, Com. /Diabetes-Endocrinol,
doi:10.1016/S2213-8587(20)30405-8Nguyen, Ho, Nguyen, Ho, Li et al., Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis, Metab.: Clin. Exp,
doi:10.1016/J.METABOL.2022.155196Orozco-Beltrán, Merino-Torres, Pérez, Cebrián-Cuenca, Párraga-Martínez et al., Diabetes does not increase the risk of hospitalization due to COVID-19 in patients aged 50 years or older in primary care-APHOSDIAB-COVID-19 multicenter study, J. Clin. Med,
doi:10.3390/jcm11082092Pal, Banerjee, Mukherjee, Bhogal, Kaur et al., Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis, 204201882199648, Ther. Adv. Endocrinol. Metab,
doi:10.1177/2042018821996482Patoulias, Doumas, Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies, Endocrinol. Metab,
doi:10.3803/ENM.2021.1048Qi, Qian, Zhang, Zhang, Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2020.03.044Qu, Zheng, Wang, Li, Liu et al., The potential effects of clinical antidiabetic agents on SARS-CoV-2, J. Diabetes,
doi:10.1111/1753-0407.13135Recalde, Data resource profile: the information system for research in primary care (SIDIAP), Int. J. Epidemiol
Recalde, Rodríguez, Burn, Far, García et al., Data resource profile: the information system for research in primary care (SIDIAP, Int. J. Epidemiol,
doi:10.1093/ije/dyac068Reynolds, Adhikari, Pulgarin, Troxel, Iturrate et al., Renin-Angiotensin-Aldosterone system inhibitors and risk of Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2008975Roberts, Pritchard, Treweeke, Rossi, Brace et al., Why Is COVID-19 more severe in patients with diabetes? the role of angiotensin-converting enzyme 2, endothelial dysfunction and the immunoinflammatory system, Front. Cardiovasc. Med,
doi:10.3389/fcvm.2020.629933Samuel, Varghese, Büsselberg, Therapeutic potential of metformin in COVID-19: reasoning for its protective role, Trends Microbiol,
doi:10.1016/j.tim.2021.03.004Who, Int. Stat. Classif. Dis. Relat. Health Probl. 10th Revis
Yan, Yang, Wang, Ren, Zhang et al., Clinical characteristics and outcomes of patients with severe covid-19 with diabetes, BMJ Open Diabetes Res. Care,
doi:10.1136/BMJDRC-2020-001343Yang, Sun, Zhang, Zhang, The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus, Diabetes Res. Clin. Pract,
doi:10.1016/j.diabres.2021.108977Yu, Li, Sun, Wang, Insulin treatment is associated with increased mortality in patients with COVID-19 and Type 2 diabetes, 65-77.e2, Cell Metab,
doi:10.1016/J.CMET.2020.11.014
